Beyond cost arbitrage: globally networked polycentric r&d addressing affordability and accessibility
- In: FIP KEYNOTE: BEYOND COST ARBITRAGE: GLOBALLY NETWORKED POLYCENTRIC R&D ADDRESSING AFFORDABILITY AND ACCESSIBILITY on Monday, 14 April 2014, 13:00-14:00
- At: PSWC, Melbourne (Australia) (2014)
- Type: Presentation
- By: BARBHAIYA, Rashmi (Advinus Therapeutics Ltd, Bangalore, India)
The introduction of the first-in-class ACE inhibitor Captopril was a phenomenal success story from a large pharma - the concept of ACE inhibition for the treatment of hypertension, identification & development of a safe & effective molecule, its manufacturing and sales/marketing was done by one company. Over the past four decades since this.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.